

REGISTERED COMPANY NUMBER: 07476120 (England and Wales)
REGISTERED CHARITY NUMBER: 1142803

Trustees' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2024
for
Global Sepsis Alliance

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2024

	Page
Trustees' Report	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9 to 10
Notes to the Financial Statements	11 to 16
Detailed Statement of Financial Activities	17 to 18

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research, and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring Our Work Delivers Our Aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees, Board, and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

Annual Activity Report - 2024 Highlights

Throughout 2024, the Global Sepsis Alliance undertook a wide range of initiatives to advance its mission of reducing the global burden of sepsis. The following summary outlines our most significant activities and achievements over the year:

Policy and Advocacy

WHO and UN Engagement: GSA's CEO, Dr. Mariam Jashi, addressed both the 154th Session of the WHO Executive Board and the 77th World Health Assembly to advocate for the inclusion of sepsis in Universal Health Coverage frameworks. GSA also participated in the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance and hosted a side event during UNGA79.

Launch of the 2030 Global Agenda for Sepsis: This initiative was formally launched in September at the German Parliament, outlining a comprehensive strategic framework to reduce sepsis deaths and long-term consequences by 2030.

Legislative Momentum in the United States: The SEPSIS Act, a bipartisan bill to enhance sepsis programs and systems, was introduced to the U.S. Senate in September with cross-party sponsorship. In parallel, the U.S. Congress allocated \$3 million to the CDC for national sepsis advocacy.

EU and Global Outreach: GSA led sepsis discussions at the UNITE Parliamentarians Global Summit, participated in the World Health Summit, and contributed to a joint sepsis policy call published in The Lancet, urging EU leaders to adopt a European Sepsis Plan.

Scientific and Clinical Leadership

2024 World Sepsis Congress Spotlight: Held in April, this online event focused on the unmet need in sepsis diagnosis and therapy. It featured nine thematic sessions covering personalized medicine, biomarkers, pediatric sepsis, AI-based prediction models, and the newly published 'Phoenix Criteria' for pediatric diagnosis. The event attracted over 12,000 participants from 185 countries, with 65% from low- and middle-income countries.

Symposium on Sepsis and the Immune System: Organized jointly with Sepsis Stiftung, this scientific symposium examined the dual role of the immune system in sepsis pathophysiology and therapeutic approaches.

Strategic Engagement with WHO: GSA contributed to the launch of WHO's website on clinical sepsis management and joined the WHO Acute Care Action Network (ACAN) to strengthen advocacy and capacity-building in acute care settings.

Partnerships and Strategic Alliances

Caribbean Sepsis Alliance Launch: GSA supported the formal establishment of the Caribbean Sepsis Alliance, with its inaugural event focusing on the intersections of climate change, health equity, and sepsis.

Memorandum of Understanding with MWIA: On International Women's Day, GSA signed a strategic partnership agreement with the Medical Women's International Association to promote gender equity and women's leadership in global health and sepsis policy.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2024

Collaborations with UNICEF and UNDP: High-level meetings with global health leaders, including UNICEF's Director of Health and representatives from the United Nations Development Programme, were held to explore joint approaches to sepsis prevention and maternal-child health.

Awareness and Public Engagement

World Sepsis Day 2024: Hundreds of awareness events were organized globally. Highlights included a video address from the WHO Director-General and formal recognition of sepsis by national health leaders. GSA also launched a virtual photo booth and published a global event poster showcasing participating organizations.

Sepsis Survivor Advocacy: GSA coordinated meetings between sepsis survivors and WHO leadership and supported survivor-led advocacy initiatives, underscoring the human impact of sepsis and the need for systemic change.

Media and Publications: GSA published full reports on its major events and initiatives and continued to provide open-access educational resources via video and podcast platforms.

Innovation and Capacity Building

Launch of the Global Sepsis Innovations Platform (GSIP): In December, GSA opened expressions of interest for its new platform focused on catalyzing innovations in sepsis diagnostics, therapies, and digital health solutions.

Inauguration of the GSA Fellowship Program: Aimed at fostering the next generation of sepsis leaders, the program was formally announced in October and is set to commence in 2025.

Governance and Stakeholder Engagement

Throughout the year, GSA held regular consultations with its members, Board of Directors, sponsors, and strategic partners. These engagements informed priority-setting for the year ahead and further strengthened GSA's collaborative approach to global advocacy.

How Our Activities Deliver Public Benefit

The Global Sepsis Alliance exists to reduce the global burden of sepsis through advocacy, education, innovation, and international collaboration. Our activities deliver clear public benefit by raising awareness of sepsis among healthcare professionals, policymakers, and the general public; promoting early recognition and timely treatment; supporting survivors and families; and contributing to the development of global health policy. Through free access to high-quality educational resources such as the World Sepsis Congress, collaboration with the World Health Organization and national governments, and support for regional alliances, we help improve sepsis outcomes worldwide - particularly in low- and middle-income countries, where the burden is greatest.

Our work aligns with public health priorities, advances the Sustainable Development Goals, and ultimately saves lives by informing and empowering both professionals and communities to act on sepsis.

Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly.

Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What Examples Exist of Who Has Benefited?

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2024

A wide range of individuals and communities have benefited from the work of the Global Sepsis Alliance. Healthcare professionals worldwide - particularly in low- and middle-income countries - have gained free access to the latest clinical knowledge and research through our educational events, such as the World Sepsis Congress and thematic symposia. Policymakers and public health authorities have drawn on our guidance and advocacy to develop or enhance national sepsis strategies, as seen with the SEPSIS Act in the United States and the launch of the 2030 Global Agenda for Sepsis. Sepsis survivors and their families have also benefited through platforms that amplify their voices, connect them with support networks, and raise public awareness. Additionally, organizations such as the Caribbean Sepsis and AMR Alliance have emerged with GSA support, enabling local responses to regional sepsis challenges. Collectively, these examples demonstrate how our work directly supports professionals, policymakers, and the public in reducing the harm caused by sepsis.

PLANS FOR FUTURE PERIODS

In 2025, the Global Sepsis Alliance will continue to expand its impact through key initiatives aimed at innovation, collaboration, and policy advancement. A central focus will be the 5th World Sepsis Congress in April, featuring over 90 expert speakers addressing cutting-edge research, personalized medicine, and global strategies for infection prevention. We will formally launch the Global Sepsis Innovations Platform (GSIP) to drive advancements in diagnostics, therapies, and digital health. In parallel, we will strengthen partnerships with international institutions, support regional alliances, and advocate for the integration of sepsis into national health plans, particularly in underserved regions. These efforts aim to accelerate progress toward the 2030 Global Agenda for Sepsis.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr Philip Taylor

Independent Examiner

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2024

REFERENCE AND ADMINISTRATIVE DETAILS

Executive Committee

Abdulelah Alhawsawi
Brett Abbenbroek
Daniela Souza
Dennis Kredler
Emmanuel Nsutebu - (Deceased November 2024)
Imrana Malik
Maha Aljuaid
Niranjan 'Tex' Kissoon
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Antonio Artigas, Brett Abbenbroek, Daniela Souza, Dennis Kredler, Emmanuel Nsutebu - (Deceased November 2024), Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Louise Thwaites, Luis Antonio Gorordo Del Sol, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Niranjan 'Tex' Kissoon, Ron Daniels, Shevin Jacob, Tobias Welte - (Deceased March 2024), Ulrika Knutsson

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Sanjay Swarup

Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2024

		2024	2023
	Notes	Unrestricted fund £	Total funds £
Income and endowments from			
Donations and legacies	2	67,357	273,926
Other trading activities	3	51,865	48,431
Total		<u>119,222</u>	<u>322,357</u>
 Expenditure on			
Raising funds	4	448,677	476,889
 NET INCOME/(EXPENDITURE)		 (329,455)	 (154,532)
 Reconciliation of funds			
Total funds brought forward		476,003	630,535
 Total funds carried forward		 <u>146,548</u>	 <u>476,003</u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2024

		2024	2023
		Unrestricted	Total
		fund	funds
	Notes	£	£
Fixed assets			
Tangible assets	9	9,831	10,101
Current assets			
Debtors	10	127,569	124,329
Cash at bank		27,088	346,918
		154,657	471,247
Creditors			
Amounts falling due within one year	11	(17,940)	(5,345)
Net current assets		136,717	465,902
Total assets less current liabilities		146,548	476,003
NET ASSETS		146,548	476,003
Funds	12		
Unrestricted funds		146,548	476,003
Total funds		146,548	476,003

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet - continued

31 December 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. DONATIONS AND LEGACIES

	2024	2023
	£	£
Donations	67,357	273,926

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

3. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Sponsorships	51,865	48,431

4. RAISING FUNDS

RAISING DONATIONS AND LEGACIES

	2024	2023
	£	£
Postage and stationery	3,498	2,810
Other direct cost	1,553	79,760
Travel subsistence & accommodation	11,339	19,053
Event costs	62,279	101,169
Support costs	370,008	274,097
	<u>448,677</u>	<u>476,889</u>

5. SUPPORT COSTS

	Management	Finance	Information technology
	£	£	£
Raising donations and legacies	352,916	508	5,866
	<u>352,916</u>	<u>508</u>	<u>5,866</u>
		Governance	
	Other	Other 2	Totals
	£	£	£
Raising donations and legacies	3,277	1,981	5,460
	<u>3,277</u>	<u>1,981</u>	<u>5,460</u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024	2023
	£	£
Depreciation - owned assets	3,277	3,367

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2024 nor for the year ended 31 December 2023.

8. STAFF COSTS

	2024	2023
	£	£
Wages and salaries	238,053	146,054
	<u>238,053</u>	<u>146,054</u>

The average monthly number of employees during the year was as follows:

2024	2023
<u> </u>	<u> </u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery	Fixtures and fittings	Computer equipment	Totals
	£	£	£	£
COST				
At 1 January 2024	838	8,172	23,103	32,113
Additions	872	-	2,135	3,007
	<u>1,710</u>	<u>8,172</u>	<u>25,238</u>	<u>35,120</u>
At 31 December 2024	1,710	8,172	25,238	35,120
DEPRECIATION				
At 1 January 2024	602	6,439	14,971	22,012
Charge for year	277	433	2,567	3,277
	<u>879</u>	<u>6,872</u>	<u>17,538</u>	<u>25,289</u>
At 31 December 2024	879	6,872	17,538	25,289
NET BOOK VALUE				
At 31 December 2024	<u>831</u>	<u>1,300</u>	<u>7,700</u>	<u>9,831</u>
At 31 December 2023	<u>236</u>	<u>1,733</u>	<u>8,132</u>	<u>10,101</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade debtors	108,037	104,590
Investment	18,639	18,639
VAT	893	1,100
	<u>127,569</u>	<u>124,329</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Social security and other taxes	3,832	3,575
Net wages	12,248	-
Accrued expenses	1,860	1,770
	<u>17,940</u>	<u>5,345</u>

12. MOVEMENT IN FUNDS

	At 1.1.24	Net movement in funds	At 31.12.24
	£	£	£
Unrestricted funds			
General fund	476,003	(329,455)	146,548
	<u>476,003</u>	<u>(329,455)</u>	<u>146,548</u>
TOTAL FUNDS	<u>476,003</u>	<u>(329,455)</u>	<u>146,548</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	119,222	(448,677)	(329,455)
	<u>119,222</u>	<u>(448,677)</u>	<u>(329,455)</u>
TOTAL FUNDS	<u>119,222</u>	<u>(448,677)</u>	<u>(329,455)</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.23	Net movement in funds	At 31.12.23
	£	£	£
Unrestricted funds			
General fund	630,535	(154,532)	476,003
TOTAL FUNDS	<u>630,535</u>	<u>(154,532)</u>	<u>476,003</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	322,357	(476,889)	(154,532)
TOTAL FUNDS	<u>322,357</u>	<u>(476,889)</u>	<u>(154,532)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.23	Net movement in funds	At 31.12.24
	£	£	£
Unrestricted funds			
General fund	630,535	(483,987)	146,548
TOTAL FUNDS	<u>630,535</u>	<u>(483,987)</u>	<u>146,548</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	441,579	(925,566)	(483,987)
TOTAL FUNDS	<u>441,579</u>	<u>(925,566)</u>	<u>(483,987)</u>

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,600 (PY - £3,450). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2024

	2024 £	2023 £
Income and endowments		
Donations and legacies		
Donations	67,357	273,926
Other trading activities		
Sponsorships	51,865	48,431
Total incoming resources	119,222	322,357
Expenditure		
Raising donations and legacies		
Postage and stationery	3,498	2,810
Other direct cost	1,553	79,760
Travel subsistence & accommodation	11,339	19,053
Event costs	62,279	101,169
	78,669	202,792
Support costs		
Management		
Wages	238,053	146,054
Computer Cost	6,155	14,855
Insurance	49,719	30,546
Office Rent	15,789	14,818
Staff welfare	240	274
Telephone	813	2,894
Advertising	-	5,794
Office cost	719	-
Bookkeeping	1,035	924
Consultancy	35,501	34,645
Foreign Exchange Loss	4,892	2,821
	352,916	253,625
Finance		
Light and heat	120	-
Bank charges	286	288
Paypal charges	102	309
	508	597
Information technology		
Website development	5,866	5,504

This page does not form part of the statutory financial statements

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2024

	2024 £	2023 £
Information technology		
Other		
Plant and machinery	277	78
Fixtures and fittings	433	578
Computer equipment	2,567	2,711
	3,277	3,367
 Other 2		
Subscription	1,981	1,320
 Governance costs		
Membership fees	-	4,464
Accountancy fees	1,860	1,770
Secretary	3,600	3,450
	5,460	9,684
 Total resources expended	448,677	476,889
 Net expenditure	 (329,455)	 (154,532)

This page does not form part of the statutory financial statements